We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Read MoreHide Full Article
Quest Diagnostics’ (DGX - Free Report) subsidiary, Haystack Oncology, and Lisata Therapeutics, Inc. (LSTA - Free Report) recently announced a research collaboration for using the Haystack MRD (minimal residual disease) technology. Under the partnership, Lisata will deploy the highly sensitive technology to detect the circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
DGX completed the validation of the Haystack MRD test in March 2024. The Haystack MRD Early Experience Program has been oversubscribed, with nearly 20 leading cancer institutions as participants, paving the way for a nationwide launch of the clinical test later this year.
More on Lisata Therapeutics
As a clinical-stage pharmaceutical company, Lisata focuses on the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.
Building on its CendR Platform Technology, Lisata has forged noteworthy commercial and R&D partnerships. The company expects to announce several clinical studies and business achievements over the next two years and projects that its available capital will fund operations into early 2026.
News in Detail
The FORTIFIDE study investigates the safety, tolerability and efficacy of certepetide when given as a four-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer. According to the estimates of the American Cancer Society, more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024, with mPDAC accounting for more than 90% of these cases. Known for its highly aggressive form, the disease mainly advances to this stage due to a lack of early diagnosis or limited patient response to treatments.
Image Source: Zacks Investment Research
The research will use Haystack’s MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide. According to a Haystack Oncology representative, the collaboration underscores the value of the Haystack MRD technology in helping drive forward the development of novel treatments for solid tumor cancers.
Designed to detect ctDNA with exceptional sensitivity, Haystack’s technology aims to provide crucial insights into ctDNA kinetics via serial measurements as an important and early indication of therapeutic response.
Industry Prospects
Per a Markets And Markets research report, the global MRD testing market was valued at $1.2 billion in 2022 and is expected to witness a CAGR of 14% by 2027. The market continues to be driven by the rising incidence and prevalence of cancer and hematological malignancies.
Notable Partnerships Involving MRD Technology
Earlier, in January 2024, Haystack Oncology announced a research collaboration with TriSalus Life Sciences to evaluate the therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
Additionally, Quest Diagnostics partnered with Ultima Genomics, involving the latter’s next-generation sequencing (NGS) technology in oncology and other clinical areas. DGX aims to deploy the Ultima technology for the possible development of lab-developed tests involving its Haystack solid-tumor MRD technology for future clinical and biopharmaceutical MRD applications, supplementing its current whole exome sequencing approach, as well as for certain future whole genome testing applications, such as rare disease detection in pediatric patients.
Price Performance
In the past year, shares of DGX have declined 2.8% against the industry’s rise of 11%.
Zacks Rank and Other Key Picks
Quest Diagnostics currently carries a Zacks Rank #2 (Buy).
Globus Medical shares have risen 20% in the past year. Estimates for the company’s earnings have remained constant at $2.82 in 2024 and at $3.32 in 2025 in the past 30 days.
GMED’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.8%. In the last reported quarter, it posted an earnings surprise of 30.9%.
Estimates for Hims & Hers Health’s 2024 earnings per share have moved upward 5.3% to 20 cents in the past 30 days. Shares of the company have surged 173% in the past year against the industry’s 22.2% fall.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 79.2%. In the last reported quarter, it delivered an earnings surprise of a staggering 150%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Quest Diagnostics’ (DGX - Free Report) subsidiary, Haystack Oncology, and Lisata Therapeutics, Inc. (LSTA - Free Report) recently announced a research collaboration for using the Haystack MRD (minimal residual disease) technology. Under the partnership, Lisata will deploy the highly sensitive technology to detect the circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
DGX completed the validation of the Haystack MRD test in March 2024. The Haystack MRD Early Experience Program has been oversubscribed, with nearly 20 leading cancer institutions as participants, paving the way for a nationwide launch of the clinical test later this year.
More on Lisata Therapeutics
As a clinical-stage pharmaceutical company, Lisata focuses on the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.
Building on its CendR Platform Technology, Lisata has forged noteworthy commercial and R&D partnerships. The company expects to announce several clinical studies and business achievements over the next two years and projects that its available capital will fund operations into early 2026.
News in Detail
The FORTIFIDE study investigates the safety, tolerability and efficacy of certepetide when given as a four-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer. According to the estimates of the American Cancer Society, more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024, with mPDAC accounting for more than 90% of these cases. Known for its highly aggressive form, the disease mainly advances to this stage due to a lack of early diagnosis or limited patient response to treatments.
Image Source: Zacks Investment Research
The research will use Haystack’s MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide. According to a Haystack Oncology representative, the collaboration underscores the value of the Haystack MRD technology in helping drive forward the development of novel treatments for solid tumor cancers.
Designed to detect ctDNA with exceptional sensitivity, Haystack’s technology aims to provide crucial insights into ctDNA kinetics via serial measurements as an important and early indication of therapeutic response.
Industry Prospects
Per a Markets And Markets research report, the global MRD testing market was valued at $1.2 billion in 2022 and is expected to witness a CAGR of 14% by 2027. The market continues to be driven by the rising incidence and prevalence of cancer and hematological malignancies.
Notable Partnerships Involving MRD Technology
Earlier, in January 2024, Haystack Oncology announced a research collaboration with TriSalus Life Sciences to evaluate the therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
Additionally, Quest Diagnostics partnered with Ultima Genomics, involving the latter’s next-generation sequencing (NGS) technology in oncology and other clinical areas. DGX aims to deploy the Ultima technology for the possible development of lab-developed tests involving its Haystack solid-tumor MRD technology for future clinical and biopharmaceutical MRD applications, supplementing its current whole exome sequencing approach, as well as for certain future whole genome testing applications, such as rare disease detection in pediatric patients.
Price Performance
In the past year, shares of DGX have declined 2.8% against the industry’s rise of 11%.
Zacks Rank and Other Key Picks
Quest Diagnostics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) and Hims & Hers Health (HIMS - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Hims & Hers Health carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks Rank #1 stocks here.
Globus Medical shares have risen 20% in the past year. Estimates for the company’s earnings have remained constant at $2.82 in 2024 and at $3.32 in 2025 in the past 30 days.
GMED’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.8%. In the last reported quarter, it posted an earnings surprise of 30.9%.
Estimates for Hims & Hers Health’s 2024 earnings per share have moved upward 5.3% to 20 cents in the past 30 days. Shares of the company have surged 173% in the past year against the industry’s 22.2% fall.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 79.2%. In the last reported quarter, it delivered an earnings surprise of a staggering 150%.